A systematic review and meta‐analysis of 18F‐labeled amyloid imaging in Alzheimer's disease. Issue 1 (1st March 2015)

• Record Type: Journal Article
• Authors: Yeo, Jing Ming; Waddell, Briony; Khan, Zubair; Pal, Suvankar
• Is Part Of: Alzheimer's & dementia. Volume 1:Issue 1(2015)
• Page Start: 5
• Page End: 13
• Publication Date: 2015-03-01
• Subjects: Alzheimer's -- Dementia -- Amyloid -- Positron emission tomography -- Florbetapir -- Florbetaben -- Flutemetamol -- Sensitivity -- Specificity; Alzheimer's disease -- Periodicals; Alzheimer's disease -- Diagnosis -- Periodicals; Dementia -- Periodicals; Dementia -- Diagnosis -- Periodicals; 616.831
• DOI: 10.1016/j.dadm.2014.11.004
• Languages: English
• ISSNs: 2352-8729

Abstract

Abstract: Background: Amyloid imaging using fluorine 18–labeled tracers florbetapir, florbetaben, and flutemetamol has recently been reported in Alzheimer's disease (AD). Methods: We systematically searched MEDLINE and EMBASE for relevant studies published from January 1980 to March 2014. Studies comparing imaging findings in AD and normal controls (NCs) were pooled in a meta‐analysis, calculating pooled weighted sensitivity, specificity, and diagnostic odds ratio (OR) using the DerSimonian‐Laird random‐effects model. Results: Nineteen studies, investigating 682 patients with AD, met inclusion criteria. Meta‐analysis demonstrated a sensitivity of 89.6%, a specificity of 87.2%, and an OR of 91.7 for florbetapir in differentiating AD patients from NCs, and a sensitivity of 89.3%, a specificity of 87.6%, and a diagnostic OR of 69.9 for florbetaben. There were insufficient data to complete analyses for flutemetamol. Conclusions: Results suggest favorable sensitivity and specificity of amyloid imaging with fluorine 18–labeled tracers in AD. Prospective studies are required to determine optimal imaging analysis methods and resolve outstanding clinical uncertainties.